All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
With a just-completed $100 million common stock financing, Flame Biosciences Inc. plans to target the inflammasome, a protein complex that sets off innate immune responses by activating the cytokines IL-1beta and IL-18.